Renal Cell Carcinoma Clinical Trials in New York, New York

10 studies are recruiting for renal cell carcinoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

   Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experimental combinations of investigational agents in participant…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   Laura and Isaac Perlmutter Cancer Center ( Site 5016), New York, New York

   Locations

   32 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07049926 on ClinicalTrials.gov

2. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

   The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Locations

   57 in total

   Run by

   Guardant Health, Inc.

   See if you can join NCT05059444 on ClinicalTrials.gov

3. Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

   This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced).…

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

   Locations

   13 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04981509 on ClinicalTrials.gov

4. A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

   The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05837767 on ClinicalTrials.gov

5. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

   Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   New York Cancer & Blood Specialists, New York, New York

   Locations

   10 in total

   Run by

   Nammi Therapeutics Inc

   See if you can join NCT06582017 on ClinicalTrials.gov

6. A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

   This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone or in combination by participants with ccRCC.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   11 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07195682 on ClinicalTrials.gov

7. Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

   The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monother…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEO-811 NYC Site, New York, New York

   Locations

   12 in total

   Run by

   Neomorph, Inc

   See if you can join NCT07300241 on ClinicalTrials.gov

8. A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

   The researchers are doing this study to find out whether it is practical (feasible) to give cemiplimab and fianlimab before a nephrectomy and whether it causes any delays with surgery in people with kidney cancer. The researchers will also look at whether cemiplimab and fianlimab given before a nep…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06699602 on ClinicalTrials.gov

9. A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

   This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patie…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   20 in total

   Run by

   HiberCell, Inc.

   See if you can join NCT06234605 on ClinicalTrials.gov

10. A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

    The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NYU Langone Health, New York, New York

    Locations

    10 in total

    Run by

    A2 Biotherapeutics Inc.

    See if you can join NCT06682793 on ClinicalTrials.gov